|
|
Volumn 11, Issue 1, 2009, Pages 37-44
|
|
Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ESTROGEN RECEPTOR;
KI 67 ANTIGEN;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
BIOSYNTHESIS;
BREAST TUMOR;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
FEMALE;
HUMAN;
METABOLISM;
METHODOLOGY;
MULTIMODALITY CANCER THERAPY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATHOLOGY;
POSTOPERATIVE PERIOD;
PROGNOSIS;
REVIEW;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS AS TOPIC;
COMBINED MODALITY THERAPY;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
KI-67 ANTIGEN;
MAGNETIC RESONANCE IMAGING;
NEOADJUVANT THERAPY;
POSTOPERATIVE PERIOD;
PROGNOSIS;
RECEPTORS, ESTROGEN;
TREATMENT OUTCOME;
|
|
EID: 63149107021
PISSN: None
EISSN: 15346269
Source Type: Journal
DOI: 10.1007/s11912-009-0007-5 Document Type: Review |
|
Times cited : (10)
|
|
References (34)
|
